# Clinical Study to Investigate the Safety and Tolerance of Therapeutic BCG in Postoperative Adjuvant Therapy in Subjects With Moderate to High-risk Non-muscular Invasive Bladder Cancer (NMIBC)

> **NCT06350838** · PHASE1 · COMPLETED · sponsor: **Chengdu CoenBiotech Co., Ltd** · enrollment: 10 (actual)

## Conditions studied

- Non-muscular Invasive Bladder Cancer

## Interventions

- **DRUG:** BCG for Therapeutic Use

## Key facts

- **NCT ID:** NCT06350838
- **Lead sponsor:** Chengdu CoenBiotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-11
- **Primary completion:** 2023-02-13
- **Final completion:** 2023-02-13
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2024-04-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06350838

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06350838, "Clinical Study to Investigate the Safety and Tolerance of Therapeutic BCG in Postoperative Adjuvant Therapy in Subjects With Moderate to High-risk Non-muscular Invasive Bladder Cancer (NMIBC)". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT06350838. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*